BiotechTube

CaPre (TM) + CaPre (TM)

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia

Trial Timeline

Sep 1, 2011 → Aug 1, 2014

NCT ID
NCT01455844

About CaPre (TM) + CaPre (TM)

CaPre (TM) + CaPre (TM) is a phase 2 stage product being developed by Grace Therapeutics for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01455844. Target conditions include Hypertriglyceridemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01455844Phase 2Completed

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors
ProductCompanyStageHype Score
LY3875383 + PlaceboEli LillyPhase 1
33
ZYH7 + ZYH7 + ZYH7 + FenofibrateZydus LifesciencesPhase 2
52
Solbinsiran + PlaceboEli LillyPhase 2
52
Placebo + Ethyl IcosapentateSumitomo PharmaPhase 3
77
Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn OilJiangsu Hengrui MedicinePhase 3
77
warfarin + omefas + omega-3-acid ethyl estersAstraZenecaPhase 1
33
rosuvastatinAstraZenecaApproved
85
Simvastatin + acetylsalicylic acid (ASA) + omefasAstraZenecaPhase 1
33
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4gAstraZenecaPhase 3
77
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)AstraZenecaPhase 2
52
rosuvastatin 40 mg tablet + Epanova™ QD (2 x 1 g capsules) + Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose + Multiple (20) oral doses of 2 g Vascepa® every 12 hoursAstraZenecaPhase 1
33
placebo + omefas + omefas + omefasAstraZenecaPhase 2/3
65
Epanova + LovazaAstraZenecaPhase 1
33
Epanova + Olive OilAstraZenecaPhase 3
77
AZD0585 + AZD0585 placeboAstraZenecaPhase 3
77
ABT-143 + simvastatinAstraZenecaPhase 3
77
MaravirocPfizerPhase 1
32
torcetrapib/atorvastatin + atorvastatinPfizerPhase 3
76
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)Mochida PharmaceuticalPhase 3
76
IcosapentMochida PharmaceuticalPhase 3
76

Other Products from Grace Therapeutics

GTX-104 + Nimotop 30 MG Oral CapsulePhase 3
69
CaPre + PlaceboPhase 3
69
CaPre + PlaceboPhase 3
69
Lipid Lowering MedicationPhase 2
44
GTX-104 + Nimodipine CapsulesPhase 1
25